Rhino Biotech Limited (RBRXF) Stock
Rhino Biotech Limited is dedicated to pioneering the development of health supplements sourced from plants and fungi, in addition to biopharmaceutical solutions designed for both disease prevention and treatment. The company adopted its current name, Rhino Biotech Limited, in September 2021, having previously operated as Eurasia Energy Limited.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About Rhino Biotech Limited
Rhino Biotech Limited is dedicated to pioneering the development of health supplements sourced from plants and fungi, in addition to biopharmaceutical solutions designed for both disease prevention and treatment. The company adopted its current name, Rhino Biotech Limited, in September 2021, having previously operated as Eurasia Energy Limited. Established in 2003, its operations are based in South Hill, Anguilla.
Rhino Biotech Limited (RBRXF) stock trades at $0.00 with a market capitalization of $3105. The stock is valued at a price-to-earnings (P/E) ratio of -0.17, price-to-book of -0.06, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.
On profitability, Rhino Biotech Limited generates a return on equity (ROE) of 42.73% — well above the market average, a sign of a high-quality business, return on capital employed of 695.71%, an operating margin of 0.00%, a net profit margin of 0.00%.
Official website: ir.rhinobiotech.com